OSLO, August 24, 2026 —

The final stretch of August delivered a cross-sectional view of modern biotech: a late-stage oncology readout with real implications, a formal regulatory request that could reshape vaccine demand, and a financing structure that signals private pain developers are still finding public-market doors. The week also included a third death in China’s expedited trial ecosystem and a study quantifying the demand-side effect of federal nutrition policy. Together, these stories do not form a single thesis; they form a set of constraints that life science investors now have to price simultaneously.

Clinical: mRNA-4157/V940 and the economics of individualized therapy

Merck (MRK) and Moderna (MRNA) produced the strongest clinical signal of the week. Their personalized cancer vaccine, mRNA-4157/V940, uses tumor-derived neoantigens to train an immune response against melanoma. Earlier Phase 2b data showed a favorable recurrence-free survival trend for the combination with Keytruda; the latest topline, reported by Endpoints News, moves the program closer to a registrational package.

The distinction between statistical significance and commercial scalability remains the central analytical question. Individualized manufacturing requires biopsy-to-treatment logistics that are structurally different from off-the-shelf checkpoint therapy. Data from the manufacturing rollout will matter as much as the efficacy curves, because the therapy’s commercial value depends on whether the manufacturing turnaround is short enough to preserve clinical benefit outside a controlled trial.

For the broader field, the Merck/Moderna result strengthens the evidence base for neoantigen-based approaches. It does not eliminate the execution risk associated with personalized medicine. Investors who treat this readout as a binary all-clear are missing the operational complexity embedded in the program.

Policy: HHS vaccine RFI alters the framing for approved products

On the regulatory side, HHS Secretary Robert F. Kennedy Jr. issued a request for information that asks how vaccine recommendations are categorized and how vaccines are tested. The document, reported by Endpoints News and STAT News, is not draft policy. It is nonetheless a formal step that could alter the advisory framework around vaccine use.

The market’s concern is not a singular ban; it is the slower erosion of broad recommendations for existing vaccines. The RFI specifically invites comment on whether some vaccines should be recommended for narrower populations. That matters for companies with large vaccine franchises, including approved products such as Moderna’s Spikevax and mRESVIA. Until the comment period closes and HHS responds, vaccine coverage assumptions carry a policy-risk discount that is separate from the clinical profile of any individual product.

The analytical frame should be structural, not political. If vaccine recommendations become more conditional, the revenue model for boosters and newer vaccines becomes less predictable. That would affect commercial planning, partnership economics, and portfolio allocation for vaccine developers even without a single regulatory rejection. The RFI is a leading indicator of that shift.

Financing: the reverse merger route is no longer an outlier

The reverse merger disclosed by Endpoints News adds another data point to a market that has not fully reopened for early-stage biotech. A California chronic pain developer with an asset approved in Italy but not the United States is entering public markets through the increasingly popular reverse merger route. The company’s co-founder, Vivek Ramaswamy, gives the deal visibility, but the structural signal is broader: private biotechs with clinical-stage assets are using reverse mergers to access listed capital when conventional IPOs remain selective.

The asset’s prior European approval does not confer FDA approval, but it does provide human efficacy data that can support U.S. registration studies. That matters because U.S. chronic pain development has been constrained by safety concerns and regulatory caution. A non-opioid pain asset with ex-U.S. evidence could, in theory, offer a differentiated profile. The reverse merger itself, however, tells us more about the capital markets than about the drug: listed shells are becoming a workable bridge for companies that cannot yet meet IPO underwriting standards.

Safety: China’s expedited trial pathway under scrutiny

The third death in China’s expedited trials, reported by Endpoints Weekly, is not a single-company story. Expedited trial pathways in China have been a convenient source of patient enrollment and early data for global sponsors. A third death raises the cost of relying on that pathway without additional safety oversight.

The investment-relevant question is not whether China’s trial system is uniformly unsafe; it is whether FDA review teams will require more independent safety monitoring for pivotal data generated under expedited Chinese protocols. That can reshape enrollment timelines and data quality for companies with China-heavy clinical strategies. It also elevates the importance of understanding which portions of a registration package are sourced from Chinese expedited trials versus standard U.S. or European sites.

Demand: SNAP soda data shows policy-driven demand shifts

Finally, the SNAP study reported by STAT News shows a 12% decline in soda purchases after restrictions on sugar-sweetened beverages. Although this is not a biotech story in the clinical sense, it belongs in the weekly framework because it measures how quickly federal nutrition policy can shift consumer demand. The authors, quoted by STAT, described the drop as meaningful but not enormous.

For biotech and healthcare investors, the lesson is that policy-driven demand shocks can arrive outside the FDA. Government purchasing restrictions can create headwinds for consumer-facing health products even when the underlying science is unchanged. That insight applies beyond soda: any product dependent on federal nutrition or reimbursement policy can be repriced by administrative action alone.

What to watch

• Merck/Moderna: full data presentation, manufacturing detail, and any regulatory submission updates, with attention to late-breaker schedules at major oncology meetings.
• HHS vaccine RFI: comment period closing date, submitted comments from industry and public health groups, and any HHS draft guidance.
• Reverse merger: closing conditions, SEC filing details, and U.S. clinical trial design for the chronic pain asset.
• China expedited trials: any FDA statements on data acceptability and sponsor disclosures about safety monitoring in pivotal trials.
• SNAP policy: peer-reviewed publication and whether USDA/HHS expand restrictions to other categories.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

NEW YORK, August 17, 2026 — The most consequential biotech signals this week did not arrive as a single clean binary clinical readout. They arrived as five separate friction points: a sharp decline in private-equity-backed physician group deals, a federal inquiry into Epic Systems, a patent suit between Cytokinetics and Bristol Myers Squibb, a Phase 3 success for an LSD-derived candidate, and a White House MMR order that pulled pediatric vaccine policy into political currents.

The common thread is not mechanism of action or therapeutic area. It is the boundary between clinical evidence and the legal, state, and federal machinery that decides whether that evidence reaches patients — and how it is paid for. That boundary is increasingly where biotech risk concentrates.

The pipeline view above positions the week’s clinical and legal flashpoints on a single continuum. It does not forecast outcomes. It shows that the relevant assets are late-stage or already marketed, which means the disputes around them are not about whether the science works. They are about control, access, and exclusivity.

Physician practice consolidators hit a state-level wall

STAT News reported that private equity deals for physician practice management firms are declining sharply, with a roughly 50 percent drop in 2026. The report points to state laws as a likely curb. This matters for biotech investors because physician practice management groups influence prescribing patterns, site-of-service economics, and the real-world data that increasingly feeds label expansion.

The decline does not necessarily mean private equity is retreating from healthcare. It means the structure of that capital is changing: smaller platforms, more state-by-state compliance, and less leverage to aggregate small practices quickly. For drug developers, a fragmented provider base can mean slower uptake of specialty therapies that require practice-level infrastructure.

Epic Systems faces the kind of scrutiny that usually follows market dominance

Epic Systems is the subject of a broad inquiry into its business practices, STAT News reported, with federal and state investigators contacting people about the company’s use of non-disclosure agreements and possible anticompetitive practices. The inquiry is not a finding, but it signals that interoperability questions have moved from academic critique to regulatory exposure.

Epic’s dominant position in hospital electronic health records makes it a bottleneck for data flow. If investigators find that contractual restrictions limit data sharing or competition, the remedies could reshape the market for real-world evidence generation. That, in turn, affects every biotech that relies on structured EHR data for post-marketing studies or label expansion.

Cytokinetics and Bristol Myers move from market rivalry to court

Cytokinetics (CYTK) filed a lawsuit against Bristol Myers Squibb (BMY) seeking to invalidate a recently granted patent protecting BMS’s cardiac myosin inhibitor franchise, Endpoints News reported. The legal action is a direct escalation in the competition between BMS’s approved mavacamten and Cytokinetics’ late-stage aficamten.

The suit does not change the clinical data, but it does raise the legal temperature around a market that cardiologists already see as a two-asset contest. Patent validity fights can delay launch timing, alter settlement leverage, and force companies to disclose more about their regulatory strategies than they would otherwise choose.

A Phase 3 LSD result reopens the neuropsychiatric development path

Endpoints Weekly reported that an LSD-derived drug cleared a Phase 3 test, alongside a recap of the Trump administration’s MMR order. The report did not name the sponsor, but the milestone is notable because it moves a psychedelic-derived candidate from exploratory to registrational territory. That is a different evidentiary bar, and it carries commercial implications well beyond a single trial.

Vaccine policy becomes a federal pediatric flashpoint

STAT News published an AAP president’s response to what the pediatrician described as federal leaders’ “fearmongering” on vaccines, following the MMR order. The investment relevance is indirect but real: vaccine confidence affects immunization rates, which affect public health demand, which affects commercial vaccine franchises.

What to watch

• Cytokinetics–Bristol Myers: Watch for early court filings on patent validity, any motion to dismiss, or signals that the parties move toward settlement rather than a full validity trial.
• Epic inquiry: Look for whether federal and state investigators escalate from informal contacts to formal civil investigative demands, and whether Epic adjusts NDA or interoperability language.
• Private equity physician deals: Watch for Q3 data from healthcare services and state-level enforcement to see whether the decline consolidates into a structural trend.
• LSD-derived candidate: Look for a company announcement with trial design details, endpoint data, and possibly an NDA/BLA filing if the Phase 3 readout supports it.
• Vaccine policy: Watch CDC implementation guidance and state public health responses to the MMR order, as well as any AAP or ACIP statements that clarify clinical practice.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

OSLO, August 10, 2026 — A sudden shortage of Sanofi’s two Pompe disease therapies rattled patient communities this week, laying bare the fragility of single‑supplier rare‑disease markets. While the immediate disruption is a clinical access problem, the scarcity lands at a moment when biotech’s geopolitical risks are intensifying on multiple fronts—from legislation targeting China‑based drug manufacturing to a broader industry reckoning with supply‑chain concentration.

The shortage involves Myozyme (alglucosidase alfa) and Nexviazyme (avalglucosidase alfa), both enzyme replacement therapies that together represent the backbone of Pompe disease management. Sanofi has not specified the root cause, but patient groups report that stockouts began appearing in major European markets in late July and have since spread to the US.1 The company’s manufacturing footprint, anchored at its Geel, Belgium facility, has been under strain before, and the opacity around the current issue leaves clinicians scrambling to adjust dosing schedules or transition patients to alternatives.

The market is not without alternatives, however. Amicus Therapeutics’ Pombiliti (cipaglucosidase alfa) co‑administered with miglustat won FDA approval in 2023 for late‑onset Pompe disease and has been steadily carving out share. A pipeline visualization of the Pompe disease landscape (see chart) shows just how concentrated the approved armamentarium is—three commercial products from two companies—while the next generation of therapies, such as Astellas’ gene therapy candidate AT845, sit in mid‑stage trials.

While a supply disruption in one rare‑disease vertical would normally be a contained story, it arrived in the same week that Senators Elissa Slotkin (D‑MI) and colleagues introduced the Biotechnology and National Security Act (BINSA) in the Senate, following earlier House action.2 The bill would restrict biotech and pharmaceutical deals involving companies with ties to the Chinese state or military, adding a new layer of national‑security screening to transactions that previously required only antitrust or CFIUS review.

The implications for supply chains are direct. Many US and European biopharma companies rely on Chinese contract manufacturing and API suppliers, especially for complex biologics and gene therapies where capacity elsewhere is tight. If BINSA passes in a form that crimps those relationships, the sort of single‑source vulnerability evident in the Sanofi Pompe shortage could become more common, not less. Existing licensing deals—such as those between large US pharma and Chinese biotechs for novel modalities—would also face new scrutiny, potentially delaying milestone payments and pipeline advancement.

The broader backdrop was dissected at an Endpoints News panel this week, where Pfizer’s Chief Data and Technology Officer Andrew Baum described China’s biotech work ethic as a “wake‑up call” for Western industry.3 The discussion, while framed as a debate on innovation speed, underscored the deep intertwinement that BINSA aims to sever. The same round‑up of industry news highlighted a mega‑merger that failed to materialize, a reflection of regulatory chill that may extend to cross‑border consolidation.

Personnel shifts, tracked by STAT News’ weekly ladder, offered a quieter signal.4 A series of senior‑level arrivals and departures across Big Pharma and mid‑size biotech suggest that companies are reshuffling for an era of tighter capital and national‑security‑aware dealmaking. None of the moves are market‑moving individually, but the aggregate picture is one of restructuring ahead of a more fragmented global operating environment.

The STAT+ opinion piece on Dr. Anthony Fauci and the origins of COVID‑19, though not a biotech business story, serves as a reminder that political friction over China’s bio‑science infrastructure is far from settled.5 For companies with significant China‑based research operations, such as BeiGene and Zai Lab, the public‑opinion currents that sustain legislative initiatives like BINSA cannot be ignored.

In the immediate term, the Sanofi shortage is a test case for how quickly a second‑source competitor can absorb displaced demand. Amicus’ manufacturing network, while smaller, has proven reliable, and its drug’s differentiated two‑component profile may make it the default fallback for patients who cannot access Myozyme or Nexviazyme. If the shortage persists beyond a single quarter, Amicus could see a material, if temporary, revenue uplift—though that is an observation about volume dynamics, not a forecast.

What to Watch

• Sanofi supply update: The company’s next communication to patient groups or a filing with EMA/FDA will be the first concrete signal of resolution. A recall or manufacturing suspension would escalate the crisis considerably.
• Astellas AT845 data: The FORTIS Phase 1/2 trial (NCT04174105) has a primary completion date in Q4 2026 according to ClinicalTrials.gov. Positive efficacy and safety data in a small cohort would both validate the gene therapy approach and expand the competitive set in Pompe disease.
• BINSA committee markup: Floor action is unlikely before the autumn, but any markup language that specifically names pharmaceutical service providers, such as WuXi Biologics, will provide a sharper read on how far the legislation reaches into existing supply chains.
• Amicus Q3 prescription trends: While company‑reported data carry bias, independent prescription audits (IQVIA, Symphony) will show whether the shortage is altering the Pompe ERT market share in real time.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

LONDON, August 3, 2026 — A week that opened with the Financial Times reporting merger discussions between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) closed with a series of developments that together illuminate the three forces now shaping biopharma: industrial consolidation, intensifying price scrutiny, and the widening gap between commercial winners and the rest.

The AZ-BMS talks, confirmed by sources cited in the FT report on Sunday, would combine two oncology-heavy portfolios into an entity with a pro forma market capitalisation exceeding $350 billion — second only to Eli Lilly among the peer set. Neither company has commented publicly. The silence itself is a signal: talks are live enough that neither side will risk scuttling them with premature disclosure.

What distinguishes this potential transaction from the sector's routine M&A speculation is the complementary logic. AstraZeneca brings strength in antibody-drug conjugates and a broad late-stage oncology pipeline. Bristol Myers contributes its established immuno-oncology franchise and a portfolio of partnered assets. The overlap in haematology — where both companies field CAR-T and bispecific programmes — would draw regulatory attention, but the strategic rationale extends beyond oncology into cardiovascular and rare disease.

The Immunology Counter-Narrative

While merger arithmetic dominated headlines, AbbVie (ABBV) spent the week demonstrating why organic commercial execution remains the sector's most reliable value driver. In its second-quarter earnings call on Thursday, executives projected confidence in Skyrizi's trajectory despite an increasingly crowded IL-23 inhibitor market.

Skyrizi generated $12.4 billion in global revenue during the first half of 2026, according to AbbVie's filing, putting the anti-IL-23 antibody on pace to exceed $25 billion for the full year. The growth comes even as Johnson & Johnson's Tremfya and newer entrants from Alumis and others compete for dermatology and gastroenterology prescriptions. AbbVie's commercial infrastructure — built over two decades of Humira dominance — has proven transferable to the next-generation asset in ways that competitors have struggled to replicate.

Endpoints News reported on July 31 that analysts had earlier questioned whether Skyrizi could maintain momentum. The first-half data provide a partial answer: the drug's expansion into inflammatory bowel disease indications has opened a second growth axis beyond psoriasis. Formulary access, built during the Humira era, has carried over.

The Political Pressure Builds

Two developments this week advanced the scrutiny of drug pricing through different institutional channels — one legislative, one judicial.

The Senate introduced language that would block a White House proposal to subject NIH research grants to political review, STAT News reported on August 2. The measure, embedded in appropriations legislation, represents a temporary but significant check on efforts to reshape how federal research funding is allocated. For biotech companies that depend on NIH-funded foundational science — essentially the entire industry — the Senate's move preserves the status quo for at least the current budget cycle.

The mechanism matters. NIH grants underpin early-stage discovery across oncology, neuroscience, and rare disease. Political filtration of grant decisions would introduce uncertainty into the basic research pipeline that feeds clinical-stage biotech. The Senate language does not resolve the tension; it defers it.

Separately, the Michigan Supreme Court ruled on August 2 that a state investigation into Eli Lilly's (LLY) insulin pricing practices may proceed. Michigan Attorney General Dana Nessel's office has alleged that Lilly charged "grossly excessive" prices for insulin products, forcing patients to ration or forgo treatment. The court's decision, reported by STAT News, allows the probe to move forward after prolonged procedural challenges.

Lilly has not commented substantively on the ruling, but the case sits within a broader pattern. State-level enforcement actions on insulin pricing have accumulated over the past three years, and the Michigan ruling removes a procedural barrier that other states have watched closely. The legal exposure is not existential for Lilly — insulin represents a shrinking portion of its revenue as GLP-1 products dominate — but the reputational cost compounds.

The Other Side of Biotech: Alnylam's Commercial Struggle

Alnylam Pharmaceuticals (ALNY) entered August under a cloud that second-quarter results did not disperse. Endpoints Weekly noted on August 1 that the company's slump has deepened, with Amvuttra's ATTR-cardiomyopathy launch failing to deliver the inflection point that analysts had anticipated.

The irony is sharp: Alnylam's RNA interference platform is among the most scientifically validated in biotechnology. The company has secured six FDA approvals across multiple indications, a record that places it in an elite cohort of platform-based biotechs. Yet Amvuttra's commercial trajectory in ATTR-CM — a market defined by Pfizer's tafamidis — has disappointed. Physician adoption has been slower than projected, and the sales force expansion intended to accelerate uptake has raised operating expenses without commensurate revenue acceleration.

Alnylam's situation illustrates a structural challenge for platform biotechs: scientific leadership does not automatically confer commercial dominance, particularly in indications where an entrenched generic or well-reimbursed branded competitor already exists. The ATTR-CM market, which Pfizer built through years of physician education and payer negotiation, has proven resistant to rapid disruption.

Synthesis: Three Fault Lines

The week's developments are not isolated. They trace three fault lines that will define biopharma's trajectory through the remainder of 2026 and into 2027.

Consolidation pressure is structural, not cyclical. The AZ-BMS talks are the latest signal that scale matters in oncology, where combination regimens and multi-indication development programmes reward broad portfolios. Patent cliffs — Bristol Myers faces loss of exclusivity on Eliquis in the coming years, while AstraZeneca's Tagrisso eventually expires — add urgency. The question is not whether consolidation continues but which combinations clear antitrust review and which do not.

Pricing scrutiny is institutionalising at multiple levels. The Michigan ruling and the Senate appropriations language operate through different mechanisms — state consumer protection law and federal funding conditions — but both reflect a political environment in which drug pricing is no longer a campaign-season talking point but a sustained governance project. Companies that treat pricing pressure as cyclical will be structurally disadvantaged relative to those that build pricing durability into development-stage decision-making.

The commercial gap between winners and the rest is widening. AbbVie's Skyrizi trajectory and Alnylam's Amvuttra launch occupy opposite ends of the commercial execution spectrum. Both companies have strong science. The difference lies in commercial infrastructure, formulary access, and therapeutic-area depth — factors that compound over time. Platform validation no longer suffices as an investment thesis; platform monetisation is the standard.

What to Watch

AZ-BMS regulatory signals. Neither company has confirmed the talks, but any formal announcement would trigger antitrust review in the EU, UK, and US. The combined haematology overlap would be the primary regulatory focus. Watch for comment from the FTC and European Commission competition directorate in the weeks following any confirmation.

AbbVie's full-year Skyrizi guidance. The company has indicated that second-half 2026 expectations will be updated at the next quarterly filing. Any upward revision would signal that the IL-23 market's growth is absorbing new entrants without margin-destructive price competition.

Senate appropriations markup. The NIH grant language must survive conference committee negotiations. If the provision is stripped, the White House proposal regains momentum. The markup timeline runs through September.

Michigan insulin probe scope. The state's investigation now proceeds to discovery. The documents sought — pricing methodologies, rebate structures, and patient assistance programme data — could establish templates for other state attorneys general. Watch for coordination signals among state-level enforcers.

Alnylam's ATTR-CM prescription data. Independent prescription-tracker data for the third quarter will indicate whether the second-quarter trajectory represented a temporary plateau or a structural ceiling. The next readout is expected in October.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

This week’s biotech news cycle delivered three separate FDA inflection points and a stark public-health metric. An advisory committee drew a narrow line on peptide compounding, Amgen mounted a data‑driven defense of a contested rare‑disease drug, and the US measles outbreak broke last year’s record with five months of transmission still ahead. Together, the events reveal an agency whose decisions are shaped by post‑pandemic safety demands, political cross‑currents, and the persistent erosion of basic vaccine coverage.

Peptide compounding: a regulatory line in the sand. On Thursday, FDA’s Pharmacy Compounding Advisory Committee voted narrowly against permitting bulk compounding of emideltide, while endorsing epitalon and a third peptide. The split reflects an agency navigating the explosion of compounding pharmacies that flourished under pandemic‑era flexibilities. Emideltide’s setback came despite high‑level support: HHS Secretary Robert F. Kennedy Jr. has publicly praised peptides and acknowledged taking them himself. Yet the panel’s vote suggests that clinical‑safety concerns still carry more weight than political endorsements when the data are thin. Compounding advocates will test that proposition again as the FDA works toward a final rule expected later this year — a document that could reshape access to dozens of peptide preparations currently sold outside traditional drug‑approval pathways (STAT News, 24 Jul 2026).

Amgen’s accelerated‑approval rematch. Amgen submitted a new independent analysis to the FDA designed to keep Tavneos (avacopan) on the market, the company disclosed on Thursday (Endpoints News, 24 Jul 2026). Tavneos won accelerated approval in 2021 for ANCA‑associated vasculitis, but post‑marketing cardiovascular signals and slow enrollment in the confirmatory trial prompted the agency to question the drug’s benefit‑risk profile earlier this year. The fresh analysis, likely a propensity score‑matched comparison or real‑world evidence dataset, mirrors a broader FDA push for robust confirmatory packages under the accelerated‑approval pathway. Even if the submission satisfies the agency, the episode underscores the growing burden on manufacturers to rapidly convert early approvals into definitive proof — a challenge that will only intensify as the FDA’s oncology and rare‑disease divisions refine their post‑market expectations.

Measles: a forecast that arrived early. The number of measles cases confirmed in the United States this year has already exceeded all of 2025, STAT reported Thursday, citing CDC data (STAT News, 24 Jul 2026). CDC has now tallied 1,354 cases in 2026, eclipsing the 1,302 infections recorded in 2025 — which was itself the highest annual count since 1992. The surge arrives before the traditional late‑summer peak, and five more months of transmission remain. The national MMR vaccination rate among kindergartners fell to 92.7% in the 2024‑2025 school year, well below the 95% threshold needed to sustain herd immunity. Eroding coverage, amplified by pandemic‑era disruptions and sustained vaccine hesitancy, has turned a preventable disease into a recurring public‑health crisis.

The commercial echo is unavoidable. Merck, which manufactures the MMR vaccine, and Moderna, which is advancing an mRNA measles candidate, will report Q2 earnings in the coming days. For vaccine makers, a record outbreak is simultaneously a public‑health failure and a demand signal — one that could prompt updated guidance on expected immunization revenues. No analyst call will be able to ignore the question.

The wider canvas. Away from the immediate regulatory drama, the Endpoints Weekly digest highlighted Anthropic’s plans to expand AI into life‑science services and Novartis CEO Vas Narasimhan’s openness to China‑focused dealmaking (Endpoints News, 25 Jul 2026). These currents sit in an uncomfortable tension: while FDA and CDC wrestle with legacy public‑health infrastructure and safety controversies, the industry is racing toward AI‑enabled discovery and emerging‑market capital. The two‑speed reality — regulatory caution at home, high ambition abroad — is likely to define biotech’s second‑half narrative.

What to watch

• FDA final rule on peptide compounding. Draft language is expected by Q4; the contours will determine whether compounding of popular peptides expands or contracts.
• Tavneos resolution. Any FDA response to Amgen’s submission — and the possibility of another advisory committee — will be a litmus test for the accelerated‑approval framework.
• CDC’s 2026‑2027 vaccination campaign. Launch details for the back‑to‑school season will signal how aggressively public‑health authorities intend to counter the measles outbreak.
• Q2 vaccine earnings. Moderna, Merck, and GSK report in the coming week; listen for commentary on measles‑related demand and manufacturing capacity.
• Novartis’s China pipeline. Any asset‑level details on new Chinese partnerships could reshape the calculus for oncology and cell‑therapy programs.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.